The Landscape of New Treatments for Eczema Our panel of experts discuss the "explosion" in new systemic and topical agents Nov 17, 2023 video
Staying Up-to-Date on Approved Therapies in Atopic Dermatitis James Del Rosso, DO, says to keep an open mind when determining the best option for patients Nov 17, 2023
Mixed Findings on Link Between Eczema and Neuropsychiatric Conditions Increased rates of OCD, anxiety, depression in adults but no clear associations in children Oct 12, 2023
Meta-Analysis Points to Most Effective Topical Treatments for Atopic Dermatitis Pimecrolimus, tacrolimus, and moderate-potency topical corticosteroids come out on top Sep 08, 2023
Atopic Dermatitis Linked to Increased IBD Risk in Adults and Kids Risk increased with severity of atopic dermatitis across both groups, cohort study shows Aug 30, 2023
Pediatric Allergic March Supported by Nationwide EHR Data Constellation of comorbid allergic conditions common among children Jul 26, 2023
'Enhanced' Eczema Treatment Cut Food Allergy Risk, but at What Cost? Early skin treatment in infants reduced weight and height compared with conventional approach Mar 29, 2023
Rapid Improvement in Atopic Dermatitis With Topical PDE4 Inhibitor Disease status, itch improved significantly within 1 to 2 weeks with roflumilast cream Mar 20, 2023
Childhood Eczema Rose in Past Two Decades, With Unexplained Racial Divides Black and multiracial children had the greatest increases in eczema Feb 22, 2023
Dupilumab Delivers in Erythrodermic Atopic Dermatitis Key clinical outcomes, inflammatory biomarkers significantly reduced with or without steroids Feb 13, 2023
IL-13 Blocker Beats Atopic Dermatitis With favorable results from three trials, approval seems likely Jan 11, 2023
Inflammation Marker May Spot Atopic Dermatitis Risk Early in Childhood Elevated TARC at 2 months more than quadrupled the likelihood of moderate-severe AD at 2 years Sep 06, 2022
Meta-Analysis of Atopic Dermatitis Drugs Favors Two JAK Inhibitors Small advantages for abrocitinib, upadacitinib, but data still accumulating for all the players Mar 30, 2022
Atopic Dermatitis: Promising Data for New Mechanistic Approach Rapid responses in a majority of patients in small trial of eblasakimab Mar 28, 2022
Extension Study Confirms JAK Inhibitor's Activity in Atopic Dermatitis EASI75 response rate exceeding 80% through 52 weeks of upadacitinib treatment Mar 16, 2022
Evidence Begins to Gel for Atopic Dermatitis, Multiple Comorbid Conditions Atopic, metabolic, cardiovascular, and mental health conditions cited in guideline update Feb 02, 2022
FDA OKs Two Oral JAK Inhibitors for Refractory Atopic Dermatitis Once-daily abrocitinib and upadacitinib join topical ruxolitinib in expanding AD market Jan 18, 2022
Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
IL-13 Inhibitor Approved for Adults With Atopic Dermatitis Significantly greater lesion clearance with tralokinumab in placebo-controlled studies Dec 28, 2021
Signs of Relief From 'Therapeutic Drought' in Atopic Dermatitis Encouraging results from pipeline agents targeting Th2-specific inflammation Nov 09, 2021
Early Success With New Target in Atopic Dermatitis Inhibition of Th2-related inflammation leads to rapid improvement in disease activity Nov 05, 2021
FDA Approves First Topical JAK Inhibitor for Atopic Dermatitis Significant skin clearance, reduced itch in majority of patients treated with ruxolitinib cream Sep 22, 2021
Oral Drug Active in Teens With Atopic Dermatitis Significant improvement at 12 weeks in 42-46% by one index, 68-72% by another Aug 24, 2021
Rapid Improvement in Atopic Dermatitis With New JAK1 Inhibitor Plus: First-in-class drug shows promise in AD, BTK inhibitor active in pemphigus May 03, 2021
Rapid Improvement in Atopic Dermatitis With Topical JAK Inhibitor Disease activity index improved as early as week 1 with delgocitinib cream Apr 27, 2021
Significant Improvement in Hand Eczema With Pan-JAK Inhibitor Disease activity indicators reduced, no safety signals with gusacitinib versus placebo Apr 26, 2021
Using the Skin Microbiome to Control Atopic Dermatitis Bacteria-based therapy shows promise in proof-of-concept trial Mar 01, 2021
Young Hidradenitis Suppurativa Patients See Lags in Care Diagnosis typically came years after disease onset; providers claim lack of knowledge on HS pain Feb 24, 2021
More Evidence for Ligelizumab in Chronic Hives Anti-IgE drug showed improved activity in omalizumab-treated patients with inadequate symptom control Nov 17, 2020
Atopic Dermatitis: New Topical Agent, Durable Results With Orals Selected abstracts from the European Academy of Dermatology and Venereology Virtual Conference Nov 02, 2020
Calcineurin Blockers for Eczema: No Cancer Signal in Big Study "Clinicians can use this evidence to counsel and reassure patients" Aug 12, 2020
Sobering Data on Risks of Short-Term Oral Corticosteroids Short steroid bursts linked to serious adverse events within a month Jul 06, 2020
Minimal Link Between Eczema and Most Cancers Study finds severe eczema tied to small risk for lymphoma Jun 30, 2020
Once-Daily Abrocitinib Succeeds for Atopic Dermatitis Oral treatment acts as JAK inhibitor Jun 05, 2020
Phase II Success for Oral CKD-Related Pruritus Agent Novel drug activates kappa opioid receptors Mar 27, 2020
IL-31 Drug Succeeds for Prurigo Nodularis Less itching and twice as many lesions resolved with investigational agent Feb 19, 2020
Xolair Improves Atopic Dermatitis Symptoms in Kids But questions remain about cost-effectiveness Nov 25, 2019
